10:00am West Coast |12:00pm Chicago |18:00 London | 20:00 Moscow


Online Webinar
Online, United Kingdom

Event Details

Join Chicago Booth Angels Network - Russia and guest speakers Andrey Kozlov, '08, and Dr. Dmitry 'Dima' Kuzmin MSc (Oxon) FRSB MIoD from 4BIO Capital for a discussion that will explore target selection, assessment, due diligence and commercial exit considerations for biotech venture investments. The conversation will be moderated by Natalia Kolupaeva, '18 (EXP-23). 


No Charge


Register Online

Deadline: 5/13/2021

Speaker Profiles

Andrey Kozlov, MBA (Speaker) '08
Co-founder and Managing Partner, 4BIO Capital

Mr Kozlov is the founding and managing Partner of 4Bio Capital, a London-based investment firm focused exclusively on advanced therapies. Before joining 4BIO Capital, Mr Kozlov worked as a Partner at Enso Ventures. With an overall 20 years' experience in finance and investments, Mr. Kozlov has an extended knowledge in Private Equity and Venture Capital.

Mr. Kozlov currently serves as board member of Redpin Therapeutics Inc and board observer of Locki Therapeutics. Mr. Kozlov also served as a Board of Directors of a specialised pharma company Egalet Corp (NASDAQ: EGLT) and Image Analysis Ltd (UK).

Mr Kozlov has an MSc with honours in Economics from the St. Petersburg University (Russia) and Master of Business Administration degree from the University of Chicago Booth School of Business (USA).

Dr. Dmitry 'Dima' Kuzmin MSc (Oxon) FRSB MIoD (Speaker)
Co-founder and Managing Partner, 4BIO Capital

Dr. Kuzmin is the founding and managing partner of 4BIO Capital, a London-based investment firm focused exclusively on advanced therapies. At 4BIO, he leads the technical team responsible for the sourcing, substantial evaluation, and post-investment management of both private and public investments. Prior to founding 4BIO, Dr. Kuzmin spent many years in academia, focusing successively on structural biology, neurochemistry, systems neuroscience, brain-computer interfaces, and gene therapy. His passion is to deliver outright cures for chronic diseases. He has served as an early-stage investor and advisor to several companies in the gene therapy space, and currently represents 4BIO Capital on the boards of Code Biotherapeutics, SparingVision, Hornet Therapeutics, Redpin Therapeutics and Araris Biotechnology.

Dr. Kuzmin holds an MSc in Biochemistry from the Lomonosov Moscow State University, a PhD in Neuroscience from MSU and MPIH Frankfurt, and an MSc (First) in Experimental Therapeutics from the University of Oxford. Dr. Kuzmin is a Fellow of the Royal Society of Biology.


Natasha Kolupaeva, '18 (EXP-23) 

Other Information

About 4BIO Capital
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.
4BIO's objective is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.